Jubilant Life Sciences posts Q1 FY18 consolidated revenue of Rs 1,596 cr

The Board of Jubilant Life Sciences has approved financial results for the quarter ended June 30, 2017.

In Q1 FY18, the company’s consolidated revenue was at Rs 1,596 crore; up 10 per cent Y-o-Y. Pharmaceuticals revenue was recorded at Rs 818 crore, contributing 51 per cent to the revenues, up eight per cent Y-o-Y, life science ingredients revenue was at Rs 737 crore, contributing 46 per cent to the revenues, up 13 per cent Y-o-Y, drug discovery solutions revenue was at Rs 41 crore, contributing three per cent to the revenues. International revenues was at Rs 1,131 crore, contributing 71 per cent to the revenues; growing eight per cent Y-o-Y.

The company posted EBITDA at Rs 344 crores and EBITDA margins were at 21.6 per cent. Pharma EBITDA was at Rs 252 crore, with margins of 30.8 per cent; contributes 70 per cent to the company’s EBITDA as against 66 per cent in Q1’FY17. Life science ingredients EBITDA was at Rs 108 crore; margins at 14.7 per cent, which contributed 30 per cent to the company’s EBITDA. The drug discovery solutions segment break even at EBITDA level.

The company’s PAT was at Rs 147 crore, with net margins at 9.2 per cent and EPS of Rs 9.44 for Re 1 FV. Capital expenditure was at Rs 98 crore and net debt reduction was at Rs 113 crore.

Commenting on the company’s performance, Shyam S Bhartia, Chairman and Hari S Bhartia, Co-Chairman and MD, Jubilant Life Sciences said, "We have started FY18 on a steady note, with our pharma segment recording its highest ever revenues during the quarter despite margin contraction in the US generics business. This performance has been led by our injectable business of niche specialty pharma which has shown double-digit growth in the last few quarters. Our life science ingredients segment delivered improved results on account of better demand and strong price environment. We continue to focus on operating cash generation to reduce our debt levels and strengthen the balance sheet."